Using daratumumab to treat T-cell leukemia that doesn't respond to chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of daratumumab-hyaluronidase in treating T-cell Acute Lymphoblastic Leukemia (T-ALL) patients who have persistent or recurrent minimal residual disease (MRD) after chemotherapy. The study aims to evaluate the rate of complete MRD response following four weekly doses of the treatment, as well as its impact on hematologic relapse-free survival and overall survival. Secondary objectives include assessing the tolerability of the treatment and its effects on patients who have undergone allogeneic stem cell transplants. The trial will utilize flow cytometry to monitor MRD status and evaluate patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient must have documented T cell ALL and must be in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy.
* Patients in hematologic CR or CRi must have persistent or recurrent MRD ≥ 10-4.
* Institution must have received central MRD status test results confirming persistent or recurrent MRD ≥ 10-4 by flow cytometry.
* Patient may have undergone a prior allogeneic stem cell transplant, but patient may not have Grafts Versus Host Disease (GVHD) that requires ongoing immunosuppressive therapy. Patient may receive prednisone if the dose is ≤ 10 mg per day.
* Patient must have an ECOG performance status 0-2.
* All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 registration to rule out pregnancy.
* Patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and continue to 3 months after the last dose of protocol treatment. Patients must also agree to abstain from donating sperm, even if they have had a successful vasectomy, or donating eggs while on study treatment and for 3 months after the last dose of protocol treatment.
* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible.
* Patient must have adequate organ and marrow function as defined below (these labs must be obtained ≤ 7 days prior to Step 1 registration).
* Absolute neutrophil count (ANC) ≥ 750/μL
* Platelets ≥ 75,000/μL
* Total or Direct bilirubin ≤ 2 mg/dL
* AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN
* Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance \> 30 ml/min
* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.
* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
* Patients with prior CNS involvement are eligible as long as they do not have active CNS involvement at time of Step 1 registration.
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.

Exclusion Criteria:

-Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used

Where it's running

• Northwestern
  Chicago, Illinois, United States Recruiting

Study contacts

• Study coordinator: Shira Dinner, MD
• Email: shira.dinner@nm.org
• Phone: 312-695-6180

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• A combination therapy for teens and young adults with relapsed or refractory T-ALL/T-LBL

  This phase 1 study tests a four-drug regimen (venetoclax, dexamethasone, bortezomib, and daratumumab) in adolescents and young adults whose T-cell ALL or T-cell lymphoblastic lymphoma has come back or not responded.

  Recruiting Phase 1 M.D. Anderson Cancer Center · Houston, Texas · NCT07513129

• Targeted immunotherapy for high-risk T-cell leukemia and lymphoma in young patients

  This study is testing a new treatment called daratumumab for young patients with high-risk T-cell leukemia and lymphoma to see if it is safe and helps improve their outcomes after a stem cell transplant.

  Recruiting at 8 sites Phase 1 New York Medical College · Phoeniz, Arizona and 15 other locations · NCT04972942

• Fewer-doses daratumumab added to VRd for newly diagnosed multiple myeloma

  This study tests whether a less-frequent daratumumab dosing plan added to VRd can help patients with newly diagnosed multiple myeloma achieve more MRD negativity.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra and 1 other locations · NCT07891923

• BCD-248 plus daratumumab in relapsed or refractory multiple myeloma

  This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.

  Recruiting at 16 sites Phase 3 Biocad · Homyel and 15 other locations · NCT07742215

• Tec Dara for newly diagnosed multiple myeloma with light chain amyloidosis

  This study tests whether tec listamab plus daratumumab can help newly diagnosed multiple myeloma with AL amyloidosis and whether the combination is safe.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai · NCT07638683

• Daratumumab for acquired immune thrombotic thrombocytopenic purpura

  This project tests whether daratumumab can raise ADAMTS13 activity in adults with acquired (immune) TTP who did not respond to or could not tolerate standard immunosuppressive treatments.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07513948

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.